← Back to patent-cliff list
Quemliclustat
Tier C — Watch / tradeQuemliclustat
Arcus Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NT5E
Indications (approved)：胰腺导管癌, Bladder cancer, Urothelial carcinoma, Renal cell carcinoma, 输尿管肿瘤, Biliary tract cancer, Bile duct cancer, Cholangiocarcinoma
Regional status
US
Phase III
2024-12-13
EU
Phase III
2024-12-13
China
-
Japan
Phase III
2024-12-13
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Quemliclustat?
Approved indications include: 胰腺导管癌, Bladder cancer, Urothelial carcinoma, Renal cell carcinoma, 输尿管肿瘤, Biliary tract cancer, Bile duct cancer, Cholangiocarcinoma.
When does the Quemliclustat patent expire?
No public expiry year is available for Quemliclustat yet; this page updates once verified.
How do I get a quote for Quemliclustat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01